Skip to main content

Advertisement

SpringerLink
Log in

The Treatment of Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis: A Systematic Review

  • Voiding Dysfunction and Lower Urinary Tract Symptoms (GH Badlani and HB Goldman, Section Editors)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

This is a systematic review on the treatment of lower urinary tract symptoms (LUTS) in patients with multiple sclerosis (MS). The heterogeneity of the outcome criteria did not allow a meta-analysis of the published evidence. In the last few decades, the therapeutic options for neurogenic bladder dysfunction have broadened. Despite this, no consensus has been reached as to the management of LUTD and LUTS in patients with MS, and the subject remains controversial. Bladder dysfunction is common in MS, affecting 80 %–100 % of patients during the course of the disease. Several studies have shown that urinary incontinence has a severe effect on patients’ quality of life, with 70 % of patients classifying the impact bladder symptoms had on their life as “high” or “moderate.” Moreover, the progressive feature of MS makes its treatment complex, since any achieved therapeutic result may be short-lived, with the possibility that symptoms will recur or develop de novo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Minardi D, Muzzonigro G. Lower Urinary Tract And Bowel Disorders And Multiple Sclerosis: Role Of Sacral Neuromodulation: A Preliminary Report. Neuromodulation. 2005;8(3):176–81.

    Article  PubMed  Google Scholar 

  2. Fjorback MV, van Rey FM, Rijnkhoff MJ, et al. Electrical Stimulation Of Sacral Dermatomes In Multiple Sclerosis Patients With Neurogenic Detrusor Overactivity. Neurourol Urodyn. 2007;26:525–30.

    Article  PubMed  CAS  Google Scholar 

  3. Crayton H, Heyman RA, Rossman HS. A Multimodal Approach To Managing The Symptoms Of Multiple Sclerosis. Neurology. 2004;63(11):S12–8.

    Article  PubMed  Google Scholar 

  4. Courtney AM, Castro-Borrero W, Davis SL, et al. Functional Treatments In Multiple Sclerosis. Curr Opin Neurobiol. 2011;24:250–4.

    Article  Google Scholar 

  5. Onal B, Siva A, Buldu I, et al. Voiding dysfunction due to multiple sclerosis: a large scale retrospective analysis. Neurourology. 2009;35(3):326–33.

    Google Scholar 

  6. Cohen BA. Identification, Causation, Alleviation, And Prevention Of Complications (ICAP): An Approach To Symptoms And Disability Management In Multiple Sclerosis. Neurology. 2008;71:S14–20.

    Article  PubMed  Google Scholar 

  7. Mahfouz W, Corcos J. Management Of Detrusor External Sphincter Dyssynergia In Neurogenic Bladder. Eur J Phys Rehabil Med. 2011;47:639–50.

    PubMed  CAS  Google Scholar 

  8. Bacsu CD, Chan L, Tse V. Diagnosing Detrusor Sphincter Dyssynergia In The Neurological Patient. BJUI. 2012;109(Supplement 3):31–4.

    Article  Google Scholar 

  9. Chartier-Kastler EJ, Ruud-Bosch JLH, Perrigot M. Long-Term Results Of Sacral Nerve Stimulation (S3) For The Treatment Of Neurogenic Refractory Urge Incontinence Related To Detrusor Hyperreflexia. J Urol. 2000;164:1476–80.

    Article  PubMed  CAS  Google Scholar 

  10. Van Rey FS, Heesakkers JP. Applications Of Neurostimulation For Urinary Storage And Voiding Dysfunction In Neurological Patients. Urol Int. 2008;81:373–8.

    Article  PubMed  Google Scholar 

  11. Fjorback MV, van Rey FS, van der Pal F, et al. Acute Urodynamic Effects Of Posterior Tibial Nerve Stimulation On Neurogenic Detrusor Overactivity In Patients With Multiple Sclerosis. Eur Urol. 2007;51:464–72.

    Article  PubMed  Google Scholar 

  12. • Elkelini MS, Abuzgaya A, Hassouna MM. Mechanisms Of Action Of Sacral Neuromodulation. Int Urogynecol J. 2010;21:S439–46. Authors discuss different ways for SNM to control various types of voiding dysfunction.

    Article  PubMed  Google Scholar 

  13. McClurg D, Ashe RG, Marshall K, et al. Comparison Of Pelvic Floor Muscle Training, Electromyography Biofeedback, And Neuromuscolar Electrical Stimulation For Bladder Ysfunction In People Wiyh Multiple Sclerosis: A Randomized Pilot Study. Neurourol Urodyn. 2006;25:337–48.

    Article  PubMed  CAS  Google Scholar 

  14. • Lucio AC, Campos RM, Perissinotto MC, et al. Pelvic Floor Muscle Training In The Treatment Of Lower Urinary Tract Dysfunction In Women With Multiple Sclerosis. Neurourol Urodyn. 2010;29:1410–3. This study supports the effectiveness of PFMT as a sole technique for the management of LUTD in MS patients.

    Article  PubMed  Google Scholar 

  15. • Khan F, Pallant JF, Pallant JI, et al. A Randomized Controlled Trial: Outcomes Of Bladder Rehabilitation In Persons With Multiple Sclerosis. J Neurol Neurosurg Psychiatry. 2010;81:1033–8. This study assesses the effectiveness of bladder rehabilitation programs in MS patients with bladder issue.

    Article  PubMed  CAS  Google Scholar 

  16. •• Lucio AC, Perissinotto MC, Natalin RA, et al. A Comparative Study Of Pelvic Floor Muscle Training In Women With Multiple Sclerosis: Its Impact On Lower Urinary Tract Symptoms And Quality Of Life. Clinics. 2011;66(9):1563–8. Authors investigate the effect of pelvic floor muscle training on LUTS and QoL in MS patients.

    Article  PubMed  Google Scholar 

  17. Shaw C, Logan K, Webber I, et al. Effect Of Clean Intermittent Self-Catheterization On Quality Of Life. JAN. 2008;61(6):641–50.

    Article  Google Scholar 

  18. Chartier-Kastler E, Denys P. Intermittent Catheterization With Hydrophilic Catheters As A Treatment Of Chronic Neurogenic Urinary Retention. Neurourol Urodyn. 2011;30:21–31.

    Article  PubMed  Google Scholar 

  19. Wein AJ. Urethral Versus Suprapubic Catheter: Choosing The Best Bladder Management For Male Spinal Cord Injury Patients With Indwelling Catheters. J Urol. 2011;185(4):1381.

    Article  PubMed  Google Scholar 

  20. Colli J, Lloyd LK. Bladder Neck Closure And Soprapubic Catheter Placement As Definitive Management Of Neurogenic Bladder. J Spinal Cord Med. 2011;34(3):273–7.

    Article  PubMed  Google Scholar 

  21. Jamison J, Maguire S, McCann J: Catheter Policies For Management Of Long Term Voiding Problems In Adults With Neurogenic Bladder Disorders. The Cochrane Library 2011;12.

  22. Chancellor MB, Anderson RU, Boone TB. Pharmacotherapy For Neurogenic Detrusor Overactivity. Am J Phys Med Rehabil. 2006;85:536–45.

    Article  PubMed  Google Scholar 

  23. •• Nicholas RS, Friede T, Hollis S, et al. Anticholinergics For Urinary Symptoms I Multiple Sclerosis. The Cochrane Library 2009:1. This review assess the absolute and comparative efficacy, tolerability and safety of anticholinergic agents in MS patients.

  24. Nicholas R, Young C, Friede T. Bladder Symptoms In Multiple Sclerosis: A Review Of Pathophysiology And Management. Expert Opin Drug Saf. 2010;9(6):905–15.

    Article  PubMed  Google Scholar 

  25. Starskin DR, Salvatore S. Oxybutinin Topical And Transdermal Formlations: An Update. Drugs Today. 2010;46(6):417–25.

    Article  Google Scholar 

  26. •• Van Rey F, Heesakkers J. Solifenacin In Multiple Sclerosis Patients With Overactive Bladder: A Prospective Study. Adv Urol. 2011. Clinical study to assess the efficacy and the effect on QoL of solifenacin for the treatment of OAB in MS patients.

  27. Hoverd PA, Fowler CJ. Desmopressin In The Treatment Of Daytime Urinary Frequency In Patients With Multiple Sclerosis. J Neurol Neurosurg Psychiatry. 1998;65:778–80.

    Article  PubMed  CAS  Google Scholar 

  28. Bosma R, Wynia K, Havlikova E, et al. Efficacy Of Desmopressin In Patients With Multiple Sclerosis Suffering From Bladder Dysfunction: A Meta-Analysis. Acta Neurol Scand. 2005;112:1–5.

    Article  PubMed  CAS  Google Scholar 

  29. Kalsi V, Fowler CJ. Therapy Insight: Bladder Dysfunction Associated With Multiple Sclerosis. Nat Clin Pract Urol. 2005;2(10):492–501.

    Article  PubMed  Google Scholar 

  30. • Zajicek JP, Apostu VI. Role Of Cannabinoids In Multiple Sclerosis. CNS Drugs. 2011;25(3):187–201. The review consider how cannabinoids may help in the management of multiple sclerosis.

    Article  PubMed  CAS  Google Scholar 

  31. • Rog DJ. Cannabis-Based Medicines In Multiple Sclerosis-A Review Of Clinical Studies. Immunobiology. 2010;215:658–72. Review on clinical results of treating MS patients with cannabinoids.

    Article  PubMed  CAS  Google Scholar 

  32. Freeman RM, Adekanmi O, Waterfield MR, et al. The Effect Of Cannabis On Urge Incontinence In Patients With Multiple Sclerosis: A Multicentre, Randomisez Placebo-Controlled Trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct. 2006;17(6):636–41.

    Article  PubMed  CAS  Google Scholar 

  33. Kavia RB, de Ridder D, Costantinescu CS, et al. Randomized Controlled Trial Of Sativex To Treat Detrusor Overactivity In Multiple Sclerosis. Mult Scler. 2010;16(11):1349–59.

    Article  PubMed  CAS  Google Scholar 

  34. Capasso R, Aviello G, Borrelli F, et al. Inhibitory Effect Of Standardized Cannabis Sativa Extract And Its Ingredient Cannabidiol On Rat And Human Bladder Contractility. Urology. 2011;77(4):1006e9–15.

    Article  Google Scholar 

  35. Pryce G, Baker D. Potential Control Of Multiple Sclerosis By Cannabis And The Endocannabinoids System. CNS Neurol Disord Drug Targets. 2012,11.

  36. Tyagi P, Tyagi V, Yoshimura N, et al. Functional Role Of Cannabinoids Receptors In Urinary Bladder. Indian J Urol. 2010;26(1):26–35.

    Article  PubMed  Google Scholar 

  37. Edmonde L, Long AF. Complementary Therapy Use By Persons With Multiple Sclerosis: Benefits And Research Priorities. Complement Ther Clin Pract. 2008;14:176–84.

    Article  Google Scholar 

  38. Olsen SA. A Review Of Complementary And Alternative Medicines (CAM) By People With Multiple Sclerosis. Occup Therap Int. 2009;16(1):57–70.

    Article  Google Scholar 

  39. Stuifbergen AK. Harrison TC; Complementary And Alternative Therapy Use In Persons With Multiple Sclerosis. Rehabil Nurs. 2003;28:14–158.

    Article  Google Scholar 

  40. Fijorbarck MV, Rijkhoff N, Petersen T, et al. Event Driven Electrical Stimulation Of The Dorsal Penile/Clitoral Nerve For Management Of Neurogenic Detrusor Overactivity In Multiple Sclerosis. Neurourol Urodyn. 2006;25:349–55.

    Article  Google Scholar 

  41. Kabay SC, Yucel M, Kabay S. Acute Effect Of Posterior Tibial Nerve Stimulation On Neurogenic Detrusor Overactivity In Patients With Multiple Sclerosis: Urodynamic Study. Urology. 2008;71(4):641–5.

    Article  PubMed  Google Scholar 

  42. Kabay S, Kabay SC, Yucel M, et al. The Clinical And Urodynamic Results Of A 3-Monh Percutaneous Posterior Tibial Nerve Stimulation Treatment In Patients With Multiple Sclerosis-Related Neurogenic Bladder Dysfunction. Neurourol Urodyn. 2009;28:964–8.

    Article  PubMed  Google Scholar 

  43. •• DeSeze M, Raibaut P, Gallien P, et al. Transcutaneous Posterior Tibial Nerve Stimulation For Treatment Of Overactive Bladder Syndrome In Multiple Sclerosis: A Multicenter Prospective Study. Neurourol Urodyn. 2011;30:306–11. This article reports the effectiveness and safeness of PTNS for OAB symptoms in MS patients.

    Article  Google Scholar 

  44. •• Gobbi C, Digesu GA, Khullar V, et al. Percutaneous Posterior Tibial Nerve Stimulation As An Effective Treatment Of Refractory Lower Urinary Tract Symptoms In Patients With Multiple Sclerosis: Preliminary Data From A Multicentre, Prospective, Open Label Trial. Mult Scler. 2011;17(12):1514–9. Authors assess subjective and objective improvement in overactive bladder symptoms in MS patients who undergo PTNS.

    Article  PubMed  CAS  Google Scholar 

  45. Herbison GP, Arnold EP. Sacral Neuromodulation With Implanted Devices For Urinary Storage And Voiding Dysfunction In Adults. The Cochrane Library. 2009, Issue 2.

  46. Bolton JF, Harrison SWC. Neuromodulation 10 Years On: How Widely Should We Use This Technique In Bladder Dysfunction? Curr Opin Urol. 2009;19:375–9.

    Article  PubMed  Google Scholar 

  47. Siddiqui NY, Wu JM, Amundsen CI. Efficacy And Adverse Events Of Sacral Nerve Stimulation For Overactive Bladder: A Systematic Review. Neurourol Urodyn. 2010;29:S18–23.

    Article  PubMed  Google Scholar 

  48. •• Chaabane W, Guillotreau J, Castel-Iacanal E, et al. Sacral Neuromodulation For Treating Neurogenic Bladder Dysfunction: Clinical And Urodynamic Study. Neurourol Urodyn. 2011;30:547–50. This article provides a comparison of efficacy of SNM in different neurological diseases.

    Article  PubMed  Google Scholar 

  49. Marinkovich SP, Gillen LM. Sacral Neuromodulation For Multiple Sclerosis Patients With Urinary Retention And Clean Intermittent Catheterization. Int Urogynecol J. 2010;21:223–8.

    Article  Google Scholar 

  50. Ruud-Bosch JLH. An Update On Sacral Neuromodulation: Where Do We Stand With This In The Management Of Lower Urinary Tract Dysfunction In 2010? BJU Int. 2010;106:1432–42.

    Article  Google Scholar 

  51. Ruud-Bosch JLH, Groen J. Treatment Of Refractory Urge Urinary Incontinence With Sacral Spinal Nerve Stimulation In Multiple Sclerosis Patients. Lancet. 1996;348:717–7719.

    Article  PubMed  CAS  Google Scholar 

  52. Scheepens WA, Jongen MMGJ, Nieman FHM, et al. Predictive Factors For Sacral Neuromodulation In Chronic Lower Urinary Tract Dysfunction. Urology. 2002;60(4):598–602.

    Article  PubMed  CAS  Google Scholar 

  53. Wallace PA, Lane FL, Noblett KL. Sacral Nerve Neuromodulation In Patients With Underlying Neurologic Disease. AJOG. 2007;197:96e1–5.

    Google Scholar 

  54. Gallien P, Reymann JM, Amarenco G, et al. Placebo Controlled, Randomised, Double Blind Study Of The Effects Of Botulinum A Toxin On Detrusor Sphincte Dyssynergia In Multiple Sclerosis Patients. J Neurol Neurosurg Psychiatry. 2005;76:1670–6.

    Article  PubMed  CAS  Google Scholar 

  55. Kuo YC, Kuo HC. Botulinum Toxin Injection For Lower Urinary Tract Dysfunction. Int J Urol. 2012.

  56. Schulte-Baukloh H, Schobert J, Stolze T, et al. Efficacy Of Botulinum-A Toxin Bladder Injections For The Treatment Of Neurogenic Detrusor Overactivity In Multiple Sclerosis Patients: An Objective And Subjective Analysis. Neurourol Urodyn. 2006;25:110–5.

    Article  PubMed  CAS  Google Scholar 

  57. Kalsi V, Gonzales G, Popat R, et al. Botulinum Injections For The Treatment Of Bladder Symptoms Of Multiple Sclerosis. Ann Neurol. 2007;62:452–7.

    Article  PubMed  CAS  Google Scholar 

  58. • Habek M, Karni A, Balash Y, et al. The Place Of Botulinum Toxin In The Management Of Multiple Sclerosis. Clin Neurol Neurosurg. 2010;112:592–6. This review summarizes current understanding on the application of botulinum in symptomatic management of MS patients.

    Article  PubMed  Google Scholar 

  59. •• Deffontaine-Rufin S, Weil M, Verollet D, et al. Botulinum Toxin A For The Treatment Of Neurogenic Detrusor Overactivity In Multiple Sclerosis Patients. Int Braz J Urol. 2011;37(5):642–8. This report evaluates the clinical and urodynamical response to the first BTX-A injection in MS patients.

    Article  Google Scholar 

  60. Hershorn S, Gajewski J, Ethans K, et al. Efficacy Of Botulinum Toxin A Injections For Neurogenic Detrusor Overactivity And Urinary Incontinence: A Randomized Double-Blind Trial. J Urol. 2011;185:2229–35.

    Article  Google Scholar 

  61. Mehnert U, Birzele J, Reuter K, et al. The Effect Of Botulinum Toxin Type A On Overactive Bladder Symptoms In Patients With Multiple Sclerosis: A Pilot Study. J Urol. 2010;184:1011–6.

    Article  PubMed  CAS  Google Scholar 

  62. Cruz F, Herschorn S, Aliotta P, et al. Efficacy Of Onambotulinumtoxina In Patients With Urinary Incontinence Due To Neurogenic Detrusor Overactivity: A Randomized Double-Blind, Placebo-Controlled Trial. Eur Urol. 2011;60:742–50.

    Article  PubMed  CAS  Google Scholar 

  63. •• Khan S, Game X, Kalsi V, et al. Long-Term Effect On Quality Of Life Of Repeat Detrusor Injections Of Botulinum Neurotoxin-A For Detrusor Overactivity In Patients With Multiple Sclerosis. J Urol. 2011;185:1344–9. Authors report the effectiveness and safety of repeated botulinum toxin injections in MS patients.

    Article  PubMed  CAS  Google Scholar 

  64. Yokoyama T, Chancellor MB, Oguma K, et al. Botulinum Toxin Type A For The Treatment Of Lower Urinary Tract Disorders. Int J Urol. 2012;19:202–15.

    Article  PubMed  CAS  Google Scholar 

  65. Tizzoni G, Foggi A. Die Wiederhestellung der harnblase. Centralbl F Chir. 1888;15:921–3.

    Google Scholar 

  66. Von Mickulitz J. Zur operation der angebarenen Blaßsen-Spalte. Zentralbl Chir. 1989;20:641–3.

    Google Scholar 

  67. Couvelaire R. Le petite vessie des tuberculeaux genito-urinaries: essai de classification, places et variants des cysto-intestinoplasties. J Urol (Paris). 1950;56:381–434.

    CAS  Google Scholar 

  68. Zachoval R, Pitha J, Medova E, et al. Augmentation cystoplasty in patients with multiple sclerosis. Urol Int. 2003;70:21–6.

    Article  PubMed  Google Scholar 

  69. Sm B. Venn SN, Greenwell TJ. The past, present and future of augmentation cystoplasty. BJU Int. 2011;109:1280–93.

    Google Scholar 

  70. Bier Holgersen R, Kiekeby LT, Nordling J. Clam Ileocystoplasty. Scand J Urol Nephrol. 1994;28:55–8.

    Article  Google Scholar 

  71. Soergel TM, Cain MP, Misseri R, Gardner TA, Koch MO, Rink RC. Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neurogenic bladder. J Urol. 2004;172:1649–52.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical and Molecular Medicine, Sant’Andrea Hospital, “Sapienza” University of Rome, Via di Grottarossa 1035, 00189, Rome, Italy

    A. Tubaro

  2. Department of Urology, Sant’Andrea Hospital, Via di Grottarossa 1035, 00189, Rome, Italy

    F. Puccini & C. De Nunzio

  3. Department of Urogynecology, St. Mary’s Hospital, Imperial College London, London, UK

    G. A. Digesu & V. Khullar

  4. National Hospital for Neurology and Neurosurgery, Queen Square, London, UK

    S. Elneil

  5. Neurocentre of Italian Switzerland, Lugano, Switzerland

    C. Gobbi

Authors
  1. A. Tubaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Puccini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. De Nunzio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. A. Digesu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Elneil
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Gobbi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. V. Khullar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Tubaro.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tubaro, A., Puccini, F., De Nunzio, C. et al. The Treatment of Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis: A Systematic Review. Curr Urol Rep 13, 335–342 (2012). https://doi.org/10.1007/s11934-012-0266-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-012-0266-9

Keywords

Search

Navigation